Mel Mann, MBA, M.Ed, Major US Army (Retired) ✓

@MelDMann · Atlanta, GA · joined 15 Jun 2009

World’s Longest Living #Gleevec & #TKI Survivor. 31 yr terminal Chronic Myeloid Leukemia #CML Survivor. Clinical Trial Pioneer. Patient Ambassador.

477 283Followers

244 169Following

36 825Posts total

383.8KViews on collected posts

Latest posts

Mel Mann, MBA, M.Ed, Major US Army (Retired) ✓@MelDMann6 Sep

Some people take every cholesterol pill they can and their numbers still won't budge. That is a scary place to sit when you're trying to stay ahead of a heart attack. Cleveland Clinic just reported one-year results from a Phase 1 CRISPR trial: a single infusion kept cutting LDL 226 views · 1 likes · 2 reposts · 0 replies Open on X →

Mel Mann, MBA, M.Ed, Major US Army (Retired) ✓@MelDMann6 Sep

I've watched too many kids fight battles no child should face. Research that keeps going is what gives families a real shot. @StJude said it plain: we won't stop until no child dies from cancer. That promise still moves me. https://t.co/FM5KpHSHSG #ClinicalResearch #Cancer htt 497 views · 0 likes · 0 reposts · 0 replies Open on X →

Mel Mann, MBA, M.Ed, Major US Army (Retired) ✓@MelDMann6 Sep

Chemo can save a life and still leave a mark on the heart years later. Too many of us only learn that trade after the damage shows up. Salk scientists found that a controlled bit of mitochondrial stress early on protected adult mice from doxorubicin heart injury — with citrate h 702 views · 2 likes · 0 reposts · 0 replies Open on X →

Mel Mann, MBA, M.Ed, Major US Army (Retired) ✓@MelDMann6 Sep

I've spent decades watching clocks in hospitals — waiting for a doctor to catch something before it gets ahead of the patient. Early warning is everything. Johns Hopkins engineers built an AI that flags sepsis in more than 40 hospitals before many clinicians even suspect it. 449 views · 0 likes · 0 reposts · 1 replies Open on X →

Mel Mann, MBA, M.Ed, Major US Army (Retired) ✓@MelDMann4 Sep

When PSA climbs again after surgery, radiation, or hormone therapy, one question matters most: where is the cancer now? Cleveland Clinic radiation oncologist Dr. Rahul Tendulkar explains how a PSMA PET scan helps answer that. It looks for prostate cancer cells across the body, h 192 views · 0 likes · 0 reposts · 0 replies Open on X →

Mel Mann, MBA, M.Ed, Major US Army (Retired) ✓@MelDMann4 Sep

They finally put a number on what blood cancer research buys: time. A Blood Cancer United analysis in Blood Advances estimates treatment advances saved 25.8 million life-years in the U.S. from 1949 through 2024. Nearly 20 million of those years came from Hodgkin lymphoma, ALL, h 222 views · 0 likes · 0 reposts · 0 replies Open on X →

Mel Mann, MBA, M.Ed, Major US Army (Retired) ✓@MelDMann4 Sep

Some lung cancers carry two mutations at once. One we already treat well. The other quietly cuts how long that treatment holds. A Phase 3 trial just published in JAMA tested that high-risk group: advanced EGFR-mutated non-small cell lung cancer with a concurrent TP53 mutation. h 374 views · 0 likes · 0 reposts · 0 replies Open on X →

Mel Mann, MBA, M.Ed, Major US Army (Retired) ✓@MelDMann4 Sep

For too many people with polycythemia vera, "treatment" still means another blood draw. PV is a chronic blood cancer that pushes the body to make too many red cells. That thickens the blood and raises the risk of clots, stroke, and heart attack. The goal is simple and hard: keep 527 views · 1 likes · 0 reposts · 0 replies Open on X →

Mel Mann, MBA, M.Ed, Major US Army (Retired) ✓@MelDMann3 Sep

Pancreatic cancer has taken too many lives with too few options. FDA has approved daraxonrasib for previously treated metastatic disease. In a 500-patient trial, median survival was 13.2 vs 6.7 months with chemo. Progress matters. Access must follow. https://t.co/lJrIp1zUQR 86 views · 0 likes · 0 reposts · 0 replies Open on X →

Mel Mann, MBA, M.Ed, Major US Army (Retired) ✓@MelDMann3 Sep

Informed consent is not paperwork. It is the line between research and using people. FDA just said good clinical practice is not optional when trials run outside the U.S. More inspections. More attention to sites where genuine consent is hard to verify. Sponsors who build a http 138 views · 0 likes · 0 reposts · 0 replies Open on X →

Mel Mann, MBA, M.Ed, Major US Army (Retired) ✓@MelDMann3 Sep

Patients sign the consent form. Then a lot of us disappear from the story. NIH just proposed that every NIH-supported clinical study share a plain-language summary of the results with the people who were in it. Not a journal article. Not a https://t.co/rZf6LOj7NQ dump. A summary 899 views · 1 likes · 2 reposts · 0 replies Open on X →

Mel Mann, MBA, M.Ed, Major US Army (Retired) ✓@MelDMann3 Sep

Same anxiety. Same racing heart. 55% bigger cortisol surge if you chronically under-drink. That’s the part most people miss. You don’t feel the difference. Your stress hormone still does. Habitual hydration sets the gain on the response. Not a glass right before the meeting. 1.1K views · 1 likes · 1 reposts · 0 replies Open on X →

Mel Mann, MBA, M.Ed, Major US Army (Retired) ✓@MelDMann27 Aug

An AI-powered system built by @HopkinsEngineer Suchi Saria and her team at Johns Hopkins now operates in over 40 hospitals nationwide, detecting sepsis before doctors may even suspect it. @CNN's @jaketapper featured the technology this week as part of the network's "AI Friend or 117K views · 54 likes · 17 reposts · 4 replies Open on X →

Mel Mann, MBA, M.Ed, Major US Army (Retired) ✓@MelDMann5 Aug

We won't stop until no child dies from cancer. 261.4K views · 7.1K likes · 342 reposts · 116 replies Open on X →

Mel Mann, MBA, M.Ed, Major US Army (Retired) ✓@MelDMann21 Oct 2015

20 yrs ago, I had terminal #Cancer with no cure in sight. Read about my miracle! https://t.co/MfHdMK7BSa #Retweet https://t.co/kWXiiOKQw3 0 views · 18.3K likes · 16K reposts · 1.8K replies Open on X →

Against accounts of the same size

14 posts from the last 90 days, next to the 100K–1M follower range. below its peers on both reach and engagement.

Median views473this account5 983median for 100K–1M

Reach, %0.10%this account1.49%median for 100K–1M

Engagement, %0.12%this account0.93%median for 100K–1M

Metric	This account	Median for 100K–1M	Ratio
Median views per post	473	5 983	0.08×
Reach (views ÷ followers)	0.10%	1.49%	0.07×
Engagement rate	0.12%	0.93%	0.13×

Others in this range → Compare with another account → How these benchmarks are built →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

261.4K5 Aug

117K27 Aug

1.1K3 Sep

899

138

5274 Sep

374

222

192

4496 Sep

702

497

226

Last 14 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

2.91%5 Aug

0.07%27 Aug

0.18%3 Sep

0.44%

0.00%

0.19%4 Sep

0.00%

0.22%6 Sep

0.28%

0.00%

1.33%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 100K–1M accounts is 0.93%.

What the audience does

Likes93.1%7 188 in total

Reposts4.7%364 in total

Replies1.6%121 in total

Quotes0.5%36 in total

Bookmarks0.1%11 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Latest posts

Against accounts of the same size

Growth & engagement

Views per post

Engagement rate per post

What the audience does

Similar accounts